foxo4-dri peptide senolytic mouse study 2023 Frontiers FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes PMC FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 an overview ScienceDirect Topics
Pay in 4 interest-free payments of $6.78 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




